Chiemi Sakai

Chiemi Sakai

Auto-generated profile, based on publicly available information

Chiemi Sakai

Department of Cardiovascular Physiology and Medicine, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Radiology
Verified
Journal Article
Closed access
HSHiroaki Sakane
Hiroaki Sakane
MIMari Ishida
Mari Ishida
LSLin Shi
Lin Shi
WFWataru Fukumoto
Wataru Fukumoto
CSChiemi Sakai
Chiemi Sakai
STSatoshi Tashiro
Satoshi Tashiro
DNA double-strand breaks and chromosome aberrations increased after a single standard-dose chest CT examination, whereas there was no difference in the number of DNA damages observed before and aft... Background Although the National Lung Screening Trial reported a significant reduction in lung cancer mortality when low-dose (LD) CT chest examinations are used for a diagnosis, their biologic eff...

7 February 2023 in Journal of the American Heart Association
Verified
Journal Article
Closed access
KKKohei Karasaki
Kohei Karasaki
HKHiroki Kokubo
Hiroki Kokubo
BBBatmunkh Bumdelger
Batmunkh Bumdelger
NKNobuchika Kaji
Nobuchika Kaji
CSChiemi Sakai
Chiemi Sakai
MYMasao Yoshizumi
Masao Yoshizumi
Background: Angiotensin II type 1 receptor blockers (ARBs) have been shown to limit the growth of abdominal aortic aneurysm (AAA), but their efficacy is controversial. This study aimed to investigate the molecular mechanism underlying the protective effect of ARBs against AAA progression. Methods and Results: Olmesartan, an ARB, was administered to wild‐type and osteoprotegerin ‐knockout ( Opg ‐KO) mice starting 2 weeks before direct application of CaCl 2 to aortas to induce AAA. The protective effect of olmesartan against AAA in wild‐type and Opg ‐KO mice was compared at 6 weeks after AAA induction. Olmesartan prevented AAA progression in Opg ‐KO mice, including excessive aortic dilatation and collapse of tunica media, but not in wild‐type mice. Deficiency of the Opg gene is known to cause excessive activation of the tumor necrosis factor–related apoptosis‐inducing ligand–induced c‐Jun N‐terminal kinase/matrix metalloproteinase 9 pathway, resulting in prolonged AAA progression. Olmesartan attenuated the upregulation of phosphorylated c‐Jun N‐terminal kinase and matrix metalloproteinase 9 expression in the aortic wall of Opg ‐KO mice. In cultured vascular smooth muscle cells, tumor necrosis factor–related apoptosis‐inducing ligand–induced c‐Jun N‐terminal kinase phosphorylation and matrix metalloproteinase 9 expression were inhibited by angiotensin (1–7), the circulating levels of which are increased by ARBs. Furthermore, administering an angiotensin (1–7) antagonist to Opg ‐KO mice diminished the protective effect of olmesartan against AAA progression. Conclusions: Olmesartan prevented AAA progression in Opg‐ KO mice by upregulating angiotensin (1–7), suggesting that angiotensin (1–7) may be a key factor that mediates the protective effect of ARBs.